Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry

Drug Testing and Analysis

Volumn 4, Issue 9, 2012, Pages 701-716

  Beuck, S ^a   Sigmund, G ^a   Koch, A ^a   Schanzer W ^a   Pokrywka, A ^b   Kwiatkowska, D ^b   Thevis, M ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b Institute of Sport National Research Institute   (Poland)

Author keywords

Doping; Prenylamine metabolism; Stimulants; TripleTOF; Urine analysis

Indexed keywords

BIOMOLECULES; BODY FLUIDS; DIRECT INJECTION; ELECTROSPRAY IONIZATION; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM;

LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PHASE I; PHENYLALKYLAMINE; PRENYLAMINE METABOLISM; STIMULANT; TRIPLETOF; UNDESIRABLE EFFECTS; URINE ANALYSIS; VENTRICULAR TACHYCARDIA;

METABOLITES;

PRENYLAMINE;

ADULT; ARTICLE; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYNTHESIS; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84866754161     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1388     Document Type: Article

References (21)

1. H. Tucker, P. Carson, N. Bass, J. Massey Prenylamine in treatment of angina. Br. Heart J. 1974, 36, 1001.
2. D. Oakley, K. Jennings, R. Puritz, D. Krikler, D. Chamberlain The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris. Postgrad. Med. J. 1980, 56, 753.
3. R. Puritz, M.A. Henderson, S.N. Baker, D.A. Chamberlain Ventricular arrhythmias caused by prenylamine. Br. Med. J. 1977, 2, 608.
4. WADA (World Anti-Doping Agency). The 2010 prohibited list. Available at: http://www.wada-ama.org/rtecontent/document/2010_Prohibited_List_FINAL_EN_Web.pdf [16 April 2012].
5. M. Donike, C.M. Kaiser Dopingkontrollen 2ndedn Bundesinstitut für Sportwissenschaft: Cologne. 1984.
6. T. Kraemer, S.K. Roditis, F.T. Peters, H.H. Maurer Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS. J. Anal. Toxicol. 2003, 27, 68.
7. I. Hornke, P. Hajdu [Studies on the metabolism of prenylamine in rats]. Arzneimittelforschung 1970, 20, 791.
8. E.K. Schmidt, G.E. von Unruh, W.D. Paar, H.J. Dengler A gas chromatographic/mass spectrometric assay for prenylamine suitable for pharmacokinetic studies of the racemate and the enantiomers. Biol. Mass Spectrom. 1992, 21, 103.
9. M. Eichelbaum, H.J. Hengstmann, H.J. Dengler [A specific and sensitive method for the analysis of prenylamine and its derivatives in biological materials]. Arzneimittelforschung 1973, 23, 74.
10. Y. Gietl, H. Spahn, H. Knauf, E. Mutschler Single- and multiple-dose pharmacokinetics of R-(-)-and S-(+)-prenylamine in man. Eur. J. Clin. Pharmacol. 1990, 38, 587.
11. Y. Gietl, H. Spahn, E. Mutschler Simultaneous determination of R- and S-prenylamine in plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1988, 426, 304.
12. G. Remberg, M. Eichelbaum, G. Spiteller, H.J. Dengler Metabolism of DL-[14C]prenylamine in man. Biomed. Mass Spectrom. 1977, 4, 297.
13. T. Kraemer, H.H. Maurer Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug Monit. 2002, 24, 277.
14. J. Ong, D.A. Parker, V. Marino, D.I. Kerr, N.M. Puspawati, R.H. Prager 3-Chloro, 4-methoxyfendiline is a potent GABA(B) receptor potentiator in rat neocortical slices. Eur. J. Pharmacol. 2005, 507, 35.
15. D.I. Kerr, J. Ong, N.M. Puspawati, R.H. Prager Arylalkylamines are a novel class of positive allosteric modulators at GABA(B) receptors in rat neocortex. Eur. J. Pharmacol. 2002, 451, 69.
16. S. Guddat, E. Solymos, A. Orlovius, A. Thomas, G. Sigmund, H. Geyer, et al. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test. Anal. 2011, 3, 836.
17. ICH. Validation of Analytical Procedures: Text and Methodology Q2 (R1). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf [16 April 2012].
18. WADA. Minimum Required Performance Levels for Detection of Prohibited Substances, WADA Technical Document TD2010MRPL. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2010MRPLv1.0_Minimum%20Required%20Performance%20Levels_Sept%2001%202010_EN.pdf [16 April 2012].
19. R. Dams, M.A. Huestis, W.E. Lambert, C.M. Murphy Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 2003, 14, 1290.
20. B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019.
21. E. Solymos, S. Guddat, H. Geyer, U. Flenker, A. Thomas, J. Segura, et al. Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Anal. Bioanal. Chem. 2011, 401, 517.